MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...

A new statistical tool that combines multiple clinical and pathologic factors with a patient's 21-gene Oncotype DX Breast Recurrence Score ® result provides more accurate estimates about that ...

There's a long-standing concern among oncologists that many women with ductal carcinoma in situ (DCIS), a potential precursor to invasive breast cancer, receive more treatment than they need. The ...

Oncotype Dx Recurrence Score (RS) is prognostic and predictive of chemotherapy benefit in women with node-negative and node-positive in hormone receptor–positive (HR+), human epidermal growth factor ...

The Oncotype DX Breast Recurrence Score® test, which has been used by over 1.5 million patients, indicates the likelihood of your cancer recurring based on the biology of your tumor. 1,2,3,4 It is ...

First clinical validation of the Oncodetect ® test to be presented in triple negative breast cancer; signals highly sensitive molecular residual disease (MRD) detection The Oncotype DX ® test is ...

A retrospective study validates the Oncotype 21-gene breast recurrence score as a predictive biomarker of adjuvant chemotherapy benefit in women with estrogen receptor (ER)-positive/human epidermal ...

—For certain older patients with low-genomic-risk, early-stage breast cancer, the findings from a new study suggest that some of them may be able to forgo either radiotherapy or endocrine therapy ...